AP2000001959A0 - Treatment of generalized anxiety disorder with paroxetine. - Google Patents

Treatment of generalized anxiety disorder with paroxetine.

Info

Publication number
AP2000001959A0
AP2000001959A0 APAP/P/2000/001959A AP2000001959A AP2000001959A0 AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0 AP 2000001959 A AP2000001959 A AP 2000001959A AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0
Authority
AP
ARIPO
Prior art keywords
paroxetine
treatment
anxiety disorder
generalized anxiety
human
Prior art date
Application number
APAP/P/2000/001959A
Other languages
English (en)
Inventor
Rocco Zaninelli
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of AP2000001959A0 publication Critical patent/AP2000001959A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/2000/001959A 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine. AP2000001959A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
PCT/US1999/008786 WO1999053919A1 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine

Publications (1)

Publication Number Publication Date
AP2000001959A0 true AP2000001959A0 (en) 2000-12-31

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001959A AP2000001959A0 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine.

Country Status (20)

Country Link
EP (1) EP1073437A4 (cs)
JP (1) JP2002512189A (cs)
KR (1) KR20010034817A (cs)
CN (1) CN1298301A (cs)
AP (1) AP2000001959A0 (cs)
AU (1) AU3864899A (cs)
BG (1) BG104939A (cs)
BR (1) BR9909791A (cs)
CA (1) CA2328896A1 (cs)
CZ (1) CZ20003885A3 (cs)
EA (1) EA200001088A1 (cs)
GB (1) GB9808479D0 (cs)
HU (1) HUP0101350A3 (cs)
ID (1) ID27546A (cs)
IL (1) IL139167A0 (cs)
NO (1) NO20005286L (cs)
PL (1) PL343494A1 (cs)
SK (1) SK15672000A3 (cs)
TR (1) TR200003082T2 (cs)
WO (1) WO1999053919A1 (cs)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
PL343494A1 (en) 2001-08-27
EP1073437A1 (en) 2001-02-07
CA2328896A1 (en) 1999-10-28
CZ20003885A3 (cs) 2001-09-12
IL139167A0 (en) 2001-11-25
GB9808479D0 (en) 1998-06-17
BR9909791A (pt) 2000-12-26
HUP0101350A2 (hu) 2002-05-29
NO20005286L (no) 2000-12-20
EP1073437A4 (en) 2003-04-16
NO20005286D0 (no) 2000-10-20
CN1298301A (zh) 2001-06-06
JP2002512189A (ja) 2002-04-23
WO1999053919A1 (en) 1999-10-28
TR200003082T2 (tr) 2001-01-22
ID27546A (id) 2001-04-12
KR20010034817A (ko) 2001-04-25
SK15672000A3 (sk) 2001-04-09
BG104939A (bg) 2001-09-28
HUP0101350A3 (en) 2002-06-28
AU3864899A (en) 1999-11-08
EA200001088A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
TW200505901A (en) Muscarinic agonists
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
AP2001002291A0 (en) Novel method of treatment.
DK0998287T3 (da) Anvendelse af levobupivacain
BE2012C040I2 (cs)
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
ATE92319T1 (de) Piperidinderivat zur schmerzbehandlung.
SI1875903T1 (sl) Zdravljenje tuberkuloze z uporabo plevromutilinskih derivatov
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
AU2003304410A8 (en) Agents and methods for treatment of disease by oligosaccharide targeting agents
EA200100653A1 (ru) Способ борьбы с членистоногими у животных
EA199800866A1 (ru) Способ снятия боли
MY122838A (en) Treating allergic and inflammatory conditions
AP2000001959A0 (en) Treatment of generalized anxiety disorder with paroxetine.
EA200100041A1 (ru) Способ лечения
TR199500984A2 (tr) Selegilin'in epileptik hastaliklarin tedavisinde kullanimi.
TR200000090T2 (tr) Serotonin'in seçici olarak yeniden yapıya alınma inhibitörleri (SSRI) kullanılarak kalp hastalıklarının tedavisi ve önlenmesi.
EA200100201A1 (ru) ПРИМЕНЕНИЕ R-(+)-α-(2, 3-ДИМЕТОКСИФЕНИЛ)-1-[2-(4-ФТОРФЕНИЛ)ЭТИЛ]-4-ПИПЕРИДИНМЕТАНОЛА ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ СНА
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components